Although some pharmas are cutting back
on internal neuroscience R&D programs, the number of precompetitive
consortia backed by industry has continued to rise, with the latest two
launching within the last two months. Most initiatives are focused on
developing better disease models and discovering new biomarkers-the challenge
going forward will be to push the boundaries of the precompetitive space to
advance the discovery of new disease-modifying targets and mechanisms.
Cain, C. SciBX 5(19); doi:10.1038/scibx.2012.483
Published online May 10, 2012
1. Ward, M. BioCentury
18(12), A6-A7; March 15, 2010
2. Hansen, S. BioCentury
20(60), A1-A4; Feb. 6, 2012
3. Osherovich, L. SciBX
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
The Biomarkers Consortium, Bethesda, Md.
CommonMind Consortium, Seattle, Wash.
Critical Path Institute, Tucson, Ariz.
European Federation of Pharmaceutical Industries and
European Medicines Agency, London, U.K.
Food and Drug Administration, Silver Spring, Md.
Foundation for the National Institutes of Health, Bethesda, Md.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark
Innovative Medicines Initiative, Brussels, Belgium
International Mental Health Research Organization, Rutherford, Calif.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
The Michael J. Fox Foundation for Parkinson's Research, New York, N.Y.
Myelin Repair Foundation, Saratoga, Calif.
National Institute on Aging, Bethesda, Md.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
One Mind for Research, Rutherford, Calif.
Sage Bionetworks, Seattle, Wash.
Structural Genomics Consortium, Oxford, U.K.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
Top Institute Pharma, Leiden, the Netherlands